Evaluating molecular biomarkers for the early detection of lung cancer: When is a biomarker ready for clinical use? An official American Thoracic Society Policy Statement

American Journal of Respiratory and Critical Care Medicine

Volumn 196, Issue 7, 2017, Pages e15-e29

  Mazzone, Peter J ^a   Sears, Catherine Rufatto ^a   Arenberg, Doug A ^a   Gaga, Mina ^a   Gould, Michael K ^a   Massion, Pierre P ^a   Nair, Vish S ^a   Powell, Charles A ^a   Silvestri, Gerard A ^a   Vachani, Anil ^a   Wiener, Renda Soylemez ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Clinical utility; Lung cancer screening; Lung nodules; Outcomes; Study design

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; HUMAN; LUNG CANCER; LUNG NODULE; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; EARLY CANCER DIAGNOSIS; LUNG NEOPLASMS; PROCEDURES; UNITED STATES;

BIOMARKERS, TUMOR; EARLY DETECTION OF CANCER; HUMANS; LUNG NEOPLASMS; SOCIETIES, MEDICAL; UNITED STATES;

EID: 85030692747     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201708-1678ST     Document Type: Review

References (39)

1. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making 1991;11:88–94.
2. Freidlin B, McShane LM, Korn EL. Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 2010;102:152–160.
3. Simon R. Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Per Med 2010;7:33–47.
4. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101: 1446–1452.
5. Micheel CM, Nass SJ, Omenn GS, editors. Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials; Board on Health Care Services; Board on Health Sciences Policy; Institute of Medicine. Chapter 4: Evaluation of omics-based tests for clinical utility and use. In: Evolution of translational omics: lessons learned and the path forward. Washington, DC: National Academies Press; 2012 [accessed 2015 Dec 15]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK202169/
6. McNeil BJ, Keller E, Adelstein SJ. Primer on certain elements of medical decision making. N Engl J Med 1975;293:211–215.
7. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC; Panel on Cost-Effectiveness in Health and Medicine. The role of cost-effectiveness analysis in health and medicine. JAMA 1996;276: 1172–1177.
8. Siegel JE, Weinstein MC, Russell LB, Gold MR; Panel on Cost-Effectiveness in Health and Medicine. Recommendations for reporting cost-effectiveness analyses. JAMA 1996;276:1339–1341.
9. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253–1258.
10. Edejer TTT, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, Murray CJL. Part 1: Methods for generalized cost-effectiveness analysis. In: Making choices in health: WHO guide to cost-effectiveness analysis. Geneva, Switzerland: World Health Organization; 2003 [accessed 2015 Dec 15]. pp. 3–97. Available from: http://www.who.int/choice/publications/p_2003_generalised_cea.pdf
11. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 2016;316:1093–1103.
12. World Health Organization. Cancer: early detection of cancer. 2017 [accessed 2015 Dec 15]. Available from: http://www.who.int/cancer/detection/en/
13. Ost DE, Gould MK. Decision making in patients with pulmonary nodules. Am J Respir Crit Care Med 2012;185:363–372.
14. Baker SG. Improving the biomarker pipeline to develop and evaluate cancer screening tests. J Natl Cancer Inst 2009;101:1116–1119.
15. Pepe MS, Janes H, Li CI, Bossuyt PM, Feng Z, Hilden J. Early-phase studies of biomarkers: what target sensitivity and specificity values might confer clinical utility? Clin Chem 2016;62:737–742.
16. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD; National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365:395–409.
17. Agency for Healthcare Research and Quality. Benefits and harms of computed tomography lung cancer screening programs for high-risk populations. AHRQ Publication No. 13-05196-EF-2. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
18. Harris RP, Sheridan SL, Lewis CL, Barclay C, Vu MB, Kistler CE, Golin CE, DeFrank JT, Brewer NT. The harms of screening: a proposed taxonomy and application to lung cancer screening. JAMA Intern Med 2014;174:281–285.
19. Bach PB, Kattan MW, Thornquist MD, Kris MG, Tate RC, Barnett MJ, Hsieh LJ, Begg CB. Variations in lung cancer risk among smokers. J Natl Cancer Inst 2003;95:470–478.
20. Spitz MR, Hong WK, Amos CI, Wu X, Schabath MB, Dong Q, Shete S, Etzel CJ. A risk model for prediction of lung cancer. J Natl Cancer Inst 2007;99:715–726.
21. Cassidy A, Myles JP, van Tongeren M, Page RD, Liloglou T, Duffy SW, Field JK. The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer 2008;98:270–276.
22. Tammemägi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, Chaturvedi AK, Silvestri GA, Riley TL, Commins J, et al. Selection criteria for lung-cancer screening. N Engl J Med 2013;368: 728–736.
23. Hoggart C, Brennan P, Tjonneland A, Vogel U, Overvad K, Østergaard JN, Kaaks R, Canzian F, Boeing H, Steffen A, et al. A risk model for lung cancer incidence. Cancer Prev Res (Phila) 2012;5:834–846.
24. Katki HA, Kovalchik SA, Berg CD, Cheung LC, Chaturvedi AK. Development and validation of risk models to select ever-smokers for CT lung cancer screening. JAMA 2016;315:2300–2311.
25. Tammemägi MC, Church TR, Hocking WG, Silvestri GA, Kvale PA, Riley TL, Commins J, Berg CD. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. PLoS Med 2014;11:e1001764.
26. Black WC, Gareen IF, Soneji SS, Sicks JD, Keeler EB, Aberle DR, Naeim A, Church TR, Silvestri GA, Gorelick J, et al.; National Lung Screening Trial Research Team. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med 2014;371:1793–1802.
27. Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, et al.; National Lung Screening Trial Research Team. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med 2013;369:920–931.
28. Gould MK, Donington J, Lynch WR, Mazzone PJ, Midthun DE, Naidich DP, Wiener RS. Evaluation of individuals with pulmonary nodules: when is it lung cancer? In: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e93S–e120S.
29. MacMahon H, Austin JH, Gamsu G, Herold CJ, Jett JR, Naidich DP, Patz EF Jr, Swensen SJ; Fleischner Society. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 2005;237:395–400.
30. Naidich DP, Bankier AA, MacMahon H, Schaefer-Prokop CM, Pistolesi M, Goo JM, Macchiarini P, Crapo JD, Herold CJ, Austin JH, et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology 2013;266:304–317.
31. Callister MEJ, Baldwin DR, Akram AR, Barnard S, Cane P, Draffan J, Franks K, Gleeson F, Graham R, Malhotra P, et al.; British Thoracic Society Pulmonary Nodule Guideline Development Group; British Thoracic Society Standards of Care Committee. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax 2015;70:ii1–ii54.
32. Swensen SJ, Silverstein MD, Ilstrup DM, Schleck CD, Edell ES. The probability of malignancy in solitary pulmonary nodules: application to small radiologically indeterminate nodules. Arch Intern Med 1997; 157:849–855.
33. Herder GJ, van Tinteren H, Golding RP, Kostense PJ, Comans EF, Smit EF, Hoekstra OS. Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography. Chest 2005;128:2490–2496.
34. Deppen SA, Blume JD, Kensinger CD, Morgan AM, Aldrich MC, Massion PP, Walker RC, McPheeters ML, Putnam JB Jr, Grogan EL. Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis. JAMA 2014;312: 1227–1236.
35. Wang Memoli JS, Nietert PJ, Silvestri GA. Meta-analysis of guided bronchoscopy for the evaluation of the pulmonary nodule. Chest 2012;142:385–393.
36. Ost DE, Ernst A, Lei X, Kovitz KL, Benzaquen S, Diaz-Mendoza J, Greenhill S, Toth J, Feller-Kopman D, Puchalski J, et al.; AQuIRE Bronchoscopy Registry. Diagnostic yield and complications of bronchoscopy for peripheral lung lesions: results of the AQuIRE Registry. Am J Respir Crit Care Med 2016;193:68–77.
37. Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR, et al. Benefits and harms of CT screening for lung cancer: a systematic review. JAMA 2012;307:2418–2429.
38. Detterbeck FC, Homer RJ. Approach to the ground-glass nodule. Clin Chest Med 2011;32:799–810.
39. Mazzone PJ. Obstacles to and solutions for a successful lung cancer screening program. Semin Respir Crit Care Med 2016;37:659–669.